Stocks · News reference

William Blair Initiates Coverage On Cytokinetics with Outperform Rating

Oct 16, 2026, 2:49 PMBenzinga Newsdesk

William Blair analyst Alethia Young initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Outperform rating.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 12, 2026, 8:02 PMBenzinga Newsdesk
Cytokinetics Presents Additional Data From Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-Obstructive HCM At HFSA Annual Scientific Meeting 2026
Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCMSOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE)
CYTK
BenzingaOct 12, 2026, 11:25 AMBenzinga Insights
Cytokinetics Q2 2026 Earnings Call: Complete Transcript
On Thursday, Cytokinetics (NASDAQ:CYTK) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
CYTK
BenzingaOct 8, 2026, 2:45 PMBenzinga Newsdesk
RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113
CYTK